123 related articles for article (PubMed ID: 18395136)
1. Fabry disease--whom to treat and when.
Mehta A
Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
[No Abstract] [Full Text] [Related]
2. Fabry disease in an oligosymptomatic male.
Altarescu G; Elstein D
Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
[No Abstract] [Full Text] [Related]
3. [Fabry disease: new clinical research--current therapeutic perspectives].
Beck M
Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
[No Abstract] [Full Text] [Related]
4. Pediatrics: implementing the promise of early intervention for Fabry disease.
Raas-Rothschild A
Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
[No Abstract] [Full Text] [Related]
5. [Intravenous lidocaine as treatment for the painful episodes in Fabry's disease].
Politei JM
Rev Neurol; 2009 Aug 1-15; 49(3):166-7. PubMed ID: 19621314
[No Abstract] [Full Text] [Related]
6. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
Warnock DG
J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
[No Abstract] [Full Text] [Related]
7. Early detection of Fabry disease: cardiac cases.
Weidemann F; Strotmann J
Clin Ther; 2008; 30 Suppl B():S46. PubMed ID: 18395138
[No Abstract] [Full Text] [Related]
8. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
9. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
Demontis R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
[TBL] [Abstract][Full Text] [Related]
10. [Fatal outcome of a patient with Fabry disease in enzymatic treatment].
Moyano MJ; del Toro N; Amor J; Milán JA
Nefrologia; 2005; 25(2):207-8. PubMed ID: 15912661
[No Abstract] [Full Text] [Related]
11. Peripheral nervous system involvement in Fabry disease: role in morbidity and mortality.
Hilz MJ
Clin Ther; 2007; 29 Suppl A():S11-2. PubMed ID: 17580234
[No Abstract] [Full Text] [Related]
12. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
13. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
14. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
15. Enzyme replacement in Anderson-Fabry disease.
Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
[No Abstract] [Full Text] [Related]
16. Fabry disease: a treatable lysosomal storage disorder.
Phadke SR; Mandal K; Girisha KM
Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement in Fabry disease: the essence is in the kidney.
Schiffmann R
Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
[No Abstract] [Full Text] [Related]
18. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
Banikazemi M; Desnick RJ
Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
[No Abstract] [Full Text] [Related]
19. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak CE; Linthorst GE
Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
[No Abstract] [Full Text] [Related]
20. Agalsidase beta (Fabrazyme) for Fabry disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
